Henry K. Lau

FDA investigator

Appears on 5 documents from 2011 to 2016, mostly at sites in California. Most often cites control of microbiological contamination (21 CFR 211.113).

5
Documents on file
8.3
Observations per 483
2011
First seen
2016
Most recent

What they cite most

From 33 observations

Activity by year

2011: 1, 2013: 1, 2014: 2, 2016: 1

Where

California 4 · Nevada 1

Is Henry K. Lau coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

5 documents, newest first
FirmOpen
483 Jajco Inc. dba Anchor Drugs PharmacyJun 3, 2016 · South San Francisco, California
Response Leiter's Compounding PharmacyMar 26, 2014 · San Jose, California
483 Leiter's Cambrian Park Drugs, Inc.Mar 6, 2014 · San Jo se, California
483 FVS Holdings, Inc. (dba Green Valley Drugs)Mar 15, 2013 · Henderson, Nevada
483 Genentech Inc.Sep 27, 2011 · South San Francisco, California

About this profile

What does Henry K. Lau inspect?

Henry K. Lau appears on 5 documents on file covering 4 sites, mostly in California.

What do they cite most often?

21 CFR 211.113 (control of microbiological contamination), followed by 21 CFR 211.42(c) and 21 CFR 211.165(a).

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Henry K. Lau is dated Jun 3, 2016.

FDA Investigator Henry K. Lau: 483s & Inspections · FDA Intel